SOURCE: Repromedix

January 09, 2008 16:01 ET

Repromedix Launches Biological Clock Test for Women

New Technology Assesses a Woman's Egg Supply -- Partners With Renowned Fertility Specialists: Boston IVF, The Jones Institute for Reproductive Medicine, Georgia Reproductive Specialists, Reproductive Medicine and Fertility Center, and Corona Institute for Reproductive Medicine & Fertility for Initial Launch

WOBURN, MA--(Marketwire - January 9, 2008) - Repromedix Corp., the leading national diagnostic laboratory for fertility testing, announces today the launch of Plan Ahead™, a new blood test that provides an assessment of a woman's egg supply by combining multiple factors including the measurement of ovary-related hormones AMH, Inhibin B, and FSH with innovative and proprietary technology. The window of opportunity for a woman to have children by natural conception is dependent upon an adequate supply of eggs which inevitably declines as a woman ages and her "biological clock ticks." Plan Ahead enables a woman to compare her estimated egg supply with the normal range expected for women of the same age.

"The Plan Ahead test represents an extraordinary advance in fertility diagnostics compared to what has been readily available to the general population," said Dr. Benjamin Leader, Chief Medical Officer. "Many fertility experts view the gold standard of egg supply measurement to be the number of eggs obtained through egg retrieval, an expensive procedure reserved for specialty fertility clinics involving hormone injections and a minimally invasive procedure. The Plan Ahead test offers similar information to the general public via a simple blood test."

Dr. Michael M. Alper, Harvard Medical School professor, and the medical director and co-founder of Boston IVF, an internationally renowned fertility treatment center, commented, "As more and more women delay pregnancy until their 30s and even their 40s, there is an urgent need for an accurate early assessment of their fertility. Unfortunately, we see far too many women late in the process when time is of the essence. The fertility field has been waiting for a test like this, and we are delighted to be the first practice to partner with Repromedix in providing this innovative test to women in the greater Boston area."

Paul Kowalski, President and VP of Sales, said, "A recent survey indicates that over 80% of women between the ages of 25-44 believe that the risk of fertility loss begins at age 35, while many experts believe the risk begins much earlier. We believe that the Plan Ahead test will provide an important tool for better education and lead to early diagnosis of potential fertility-related issues."

"For more than 14 years, Repromedix has been a pioneer and leader in the field of sophisticated reproductive diagnostics working in partnership with leading reproductive specialists across the country to help people start families," said Dr. Michael Burns, Chief Executive Officer. "Plan Ahead represents a new chapter in Repromedix's history. We are extraordinarily proud to be able to offer this innovative product with clinical validation and endorsement by some of the most well-respected fertility experts in the country. We look forward to the near future when Plan Ahead becomes the standard of care in assessing female fertility."

Repromedix introduces the Plan Ahead test today in Boston, Atlanta, Corona (CA), Norfolk (VA), Denver and Colorado Springs with strategic partnerships with the renowned fertility clinics: Boston IVF, Georgia Reproductive Specialists, The Jones Institute for Reproductive Medicine (VA), Reproductive Medicine & Fertility Center (CO), and the Corona Institute for Reproductive Medicine & Fertility (CA). The Company expects to make the test available in New York, Chicago, Los Angeles, Miami, Fort Lauderdale, Columbia (SC), Raleigh, Indianapolis and Dallas in the near future. The suggested cost of the Plan Ahead test is $350. Women interested in obtaining the Plan Ahead test are encouraged to visit the Company's website:

About Repromedix (

Repromedix is the leading national diagnostic laboratory for fertility testing and offers a multifaceted approach to clinical fertility testing that encompasses many medical disciplines including endocrinology, immunology and genetics. Repromedix offers the most comprehensive suite of advanced diagnostic tests that provide valuable information regarding the complex problems of reproductive failure. Since its inception in 1993, the company has assisted more than 45,000 patients by performing over 100,000 diagnostic tests for recurrent pregnancy loss, premature ovarian failure, male infertility, and unexplained infertility. Repromedix is a portfolio company of Brook Venture Partners, Ironwood Capital Management, and Brooke Private Equity Advisors.

About Boston IVF (

Established in 1986, Boston IVF is one of America's most successful fertility centers. Using a team approach to meet every aspect of patients' needs, Boston IVF is committed to giving everyone the chance to build a family. Boston IVF provides patients with unparalleled medical care and the best experience with the expertise of premier doctors and professional staff, who are affiliated with Harvard Medical School. It is world renowned for its highly successful and innovative infertility treatments, highest quality service, state-of-the-art methods, ongoing scientific research, and on-site complementary healthcare at its Domar Center. Boston IVF has convenient locations in Waltham, MA, Brookline, MA, and Quincy, MA, and its doctors see patients at leading hospitals throughout Massachusetts and Maine.

About The Jones Institute for Reproductive Medicine (

The Jones Institute has been an active and prolific leader of scientific advances in infertility treatment worldwide with outstanding contributions to the specialty of reproductive biology. The Company continues to seek innovative ways to improve infertility treatments with a unique combination of proven clinical protocols and advanced research and development techniques that provide an unmatched environment for treating infertility and provide compassionate care for our patients.

About Reproductive Medicine and Fertility Centers


Reproductive Medicine & Fertility Centers was established in 1998 with two goals in mind: "High Tech with a Personal Touch™" and "Healing by Creating Families™." RMFC is founded by Dr. Paul C. Magarelli, MD, Ph.D. Dr. Magarelli had a career that started as a Ph.D. in reproduction of marine animals and transitioned to humans, via medical school, to launch a network of RE&I centers (Colorado, New Mexico, California) that specialize in advanced reproductive technologies, novel financial programs, national leadership in research and development and a commitment to patient and academic excellence. Dr. Magarelli's team consists of Embryologist trained in the latest PGD technology, and Ph.D. administrators that develop cost-effective care. Dr. M. Mitwally, a patent holder in Aromatase Inhibitors, leads the research division of RMFC and RMFC is proud that we have been selected to host International RE&I Fellows in their career development. Our mottos reflect a commitment to the highest quality patient care while recognizing our responsibility to develop new and improved ways of helping our couples create families.

About Georgia Reproductive Specialists (

Georgia Reproductive Specialists (GRS) applies medical science's most advanced fertility technologies to provide the highest standards of patient-centered, reproductive healthcare. The staff at GRS, including infertility laboratory pioneer Michael Tucker, Ph.D., is focused on providing individualized, innovative solutions for reproductive challenges and infertility, specializing in in vitro fertilization, intracytoplasmic sperm injection and other assisted reproductive technologies. Fellowship-trained reproductive endocrinologists Dr. Susan C. Conway, Dr. Carolyn Kaplan, Dr. Mark Perloe and Dr. Eric Scott Sills, are experts in female and male disorders including polycystic ovary syndrome (PCOS), repeated pregnancy loss, menstrual disorders and azoospermia. GRS has three offices, Atlanta, Alpharetta and Decatur, to conveniently serve patients across Metro Atlanta.

Contact Information